Victory Medical Center Pharmacy Recalls Compounded Glutathione Vials Across Three States Over Elevated Endotoxin Levels

Adverse events including fever, hypotension, tachycardia, and injection site reactions have already been reported, a signal that Victory Medical Center Pharmacy's voluntary recall of Compounded Glutathione 200 mg/mL Multi-Dose Vials reflects a sterility assurance failure with direct patient-harm consequences, not a precautionary paperwork exercise.

The Austin, Texas-based 503A compounder initiated the recall on August 5, 2026, after internal testing identified elevated bacterial endotoxin levels across three lot numbers: 198057, 198194, and 198434, all carrying an expiration date of August 27, 2026. Affected product was distributed to consumers in Texas, Florida, and New York. The FDA's risk statement assigns a reasonable probability of serious medical events, including anaphylactic shock and death, to injectable product carrying endotoxin loads above specification.

For QA directors and compounding oversight leads, the case raises a pointed question about endotoxin control strategy. Multi-dose injectable vials compounded under 21 CFR Part 211 and USP <85> Bacterial Endotoxins Test requirements demand validated limulus amebocyte lysate (LAL) testing at release. The fact that pharmacy testing, rather than a pre-distribution quality gate, identified the exceedance suggests the detection occurred post-release or at a late-stage check, a gap that CAPA documentation will need to address explicitly.

The recall extends to the patient level, with Victory Medical Center Pharmacy conducting outreach by telephone and mail and arranging product retrieval. Prescribers and patients holding affected lots are directed to quarantine product immediately, cease administration, and contact the pharmacy at (512) 279-0985 for retrieval logistics. Full refunds are being issued for unreimbursed product.

Adverse events and quality complaints can be submitted to FDA's MedWatch program online at www.fda.gov/medwatch/report.htm or by calling 1-800-332-1088. For compounding pharmacies operating under 503A or 503B frameworks, this recall reinforces that endotoxin specification setting, in-process controls, and release testing intervals for multi-dose injectables remain active inspection focal points.

The breadth of reported adverse events across multiple organ systems will likely inform how FDA reviewers assess this pharmacy's corrective action plan and whether the endotoxin exceedance reflects a systemic gap in the facility's pharmaceutical quality system.

Source: FDA Safety Recalls, Market Withdrawals and Safety Alerts via FDA.gov, August 5, 2026.